Filter Results
:
(623)
Show Results For
-
All HBS Web
(623)
- People (2)
- News (55)
- Research (438)
- Events (2)
- Multimedia (5)
- Faculty Publications (386)
Show Results For
-
All HBS Web
(623)
- People (2)
- News (55)
- Research (438)
- Events (2)
- Multimedia (5)
- Faculty Publications (386)
- Web
Vault | Baker Library | Bloomberg Center | Harvard Business School
Individual Account Access notes To access Vault Guides, click on The Library and then Guides. HBS alumni version available via eBaker. Individual account required- use HBS email address to register. Related Resources Biotechnology...
View Details
- 12 Apr 2022
- Blog Post
The Many Languages of Medicine to Impact Care Delivery
their suffering is extremely compelling and was the catalyst for my pursuit of an MS/MBA in Biotechnology degree. As a joint degree student, I benefit from immersive case studies at HBS where my classmates and I are challenged to analyze...
View Details
- January 2001
- Case
Abgenix and the XenoMouse
By: Robert J. Dolan
Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early 2000, the company's cancer has performed very well in animal testing and is moving to early stage human testing. Abgenix must decide whether to...
View Details
Keywords:
Product Development;
Marketing Strategy;
Health Testing and Trials;
Risk and Uncertainty;
Technological Innovation;
Innovation Strategy;
Science-Based Business;
Biotechnology Industry
Dolan, Robert J. "Abgenix and the XenoMouse." Harvard Business School Case 501-061, January 2001.
- October 2007 (Revised July 2013)
- Case
Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech
By: Robert F. Higgins, Sophie LaMontagne and Brent Kazan
In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates into development. However, several questions related to...
View Details
Keywords:
Philanthropy;
Philanthropy Funding;
Innovation;
Funding Model;
Venture Capital;
Partners and Partnerships;
Financing and Loans;
Investment Funds;
Acquisition;
Philanthropy and Charitable Giving;
Biotechnology Industry;
Biotechnology Industry;
San Diego
Higgins, Robert F., Sophie LaMontagne, and Brent Kazan. "Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech." Harvard Business School Case 808-005, October 2007. (Revised July 2013.)
- 01 Oct 2021
- News
From Scholarship to Life-Saving Impact
focused on patients. “Patients and their families are at the center of why I want to be in the biotechnology space,” she concludes. “When you’re working on rare diseases, it’s hard not to feel like you’re making a difference.”
View Details
- Web
Informa (In Vivo, MedTech Insight, Scrip) | Baker Library | Bloomberg Center | Harvard Business School
platform. Related Resources Medical Devices Pharmaceuticals Database AttributesCoverageIn Vivo - latest 3 months; MedTech - Most recent 1 year(s) 6 month(s) available; Start-up?Categories Industry Specific Databases Industry Specific News Healthcare & Hospitals View Details
- 17 Sep 2021
- Research & Ideas
The Trial of Elizabeth Holmes: Visionary, Criminal, or Both?
Former Theranos employees began testifying this week against Elizabeth Holmes, the once-celebrated biotech’s founder and CEO, in a criminal trial that has Silicon Valley worried. In opening statements last week, federal prosecutors charged that Holmes and the company’s...
View Details
- Web
VitalLaw | Baker Library | Bloomberg Center | Harvard Business School
commercial use is allowed. Related Resources Biotechnology Energy Capital Changes Database AttributesCategories Mergers & Acquisitions Bankruptcy Company Histories Companies & Industries Legal & Regulatory Legal Cases & Law Reviews Policy...
View Details
- November 2020
- Case
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage...
View Details
Keywords:
Mergers and Acquisitions;
Value;
Valuation;
Judgments;
Decision Making;
Cash Flow;
Financial Instruments;
Cognition and Thinking;
Biotechnology Industry;
Biotechnology Industry;
United States
Esty, Benjamin C., and Daniel Fisher. "Valuing Celgene's CVR." Harvard Business School Case 221-031, November 2020.
- Web
Student Spotlight: 2023 HCC Co-Presidents Reflect on Their Time at HBS and the Current Health Care Systems - Blog: Health Supplement
life sciences. They complemented the case method with applied learning through projects and written assignments–for example, a mock diligence report for a biotechnology company. Most importantly, the professors were phenomenal; they...
View Details
- December 2005 (Revised August 2006)
- Case
Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug
By: Felix Oberholzer-Gee and Dennis A. Yao
Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and...
View Details
Keywords:
Health Care and Treatment;
Strategic Planning;
Competition;
Patents;
Innovation and Invention;
Biotechnology Industry;
Biotechnology Industry;
United States
Oberholzer-Gee, Felix, and Dennis A. Yao. "Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug." Harvard Business School Case 706-454, December 2005. (Revised August 2006.)
- April 2023
- Case
Drive Capital: A New Road for Venture
By: Paul A. Gompers and Alicia Dadlani
Founded by two former Sequoia Capital partners, Columbus-Ohio-based Drive Capital’s mission was to build a world-class venture capital firm in the middle of the U.S., an area historically overlooked by VCs. Drive faced early challenges of attracting investors, sourcing...
View Details
Keywords:
Venture Capital;
Business Startups;
Entrepreneurship;
Investment;
Business Strategy;
Biotechnology Industry;
Biotechnology Industry;
United States;
Ohio
Gompers, Paul A., and Alicia Dadlani. "Drive Capital: A New Road for Venture." Harvard Business School Case 823-056, April 2023.
- 18 Nov 2002
- Research & Ideas
Where Morals and Profits Meet: The Corporate Value Shift
information technologies. Recent advances in biotechnology have raised ethical issues that have never before presented themselves. And globalization has given rise to cross-cultural dilemmas that just weren't a major part of the scene in...
View Details
Keywords:
by Carla Tishler
- January 2014 (Revised June 2015)
- Case
Amgen Inc.: Pursuing Innovation and Imitation? (A)
By: Ian W. Mackenzie
Set in 2009, the (A) case explores whether Amgen, a leading innovator of biotech-based drugs, should enter the emerging business of biosimilars (BS), which are essentially 'me-too' products. There appear to be sound reasons to explore this related diversification:...
View Details
Mackenzie, Ian W. "Amgen Inc.: Pursuing Innovation and Imitation? (A)." Harvard Business School Case 714-424, January 2014. (Revised June 2015.)
- October 2004 (Revised March 2005)
- Case
Langer Lab, The: Commercializing Science
By: H. Kent Bowen, Alex Kazaks, Ayr Muir-Harmony and Bryce LaPierre
Professor Robert Langer's laboratory at MIT is the source of an unusually large number of published papers, patents, and technology licenses to start-up and established companies in the biomedical industry. Explores Langer's leadership and other factors that create a...
View Details
Keywords:
Entrepreneurship;
Technological Innovation;
Business Startups;
Research and Development;
Patents;
Innovation Leadership;
Science-Based Business;
Commercialization;
Biotechnology Industry;
Biotechnology Industry
Bowen, H. Kent, Alex Kazaks, Ayr Muir-Harmony, and Bryce LaPierre. "Langer Lab, The: Commercializing Science." Harvard Business School Case 605-017, October 2004. (Revised March 2005.)
- 12 Jun 2018
- Research & Ideas
In a Landscape of 'Me Too' Drug Development, What Spurs Radical Innovation?
portfolios. They examined all companies that held at least one drug patent on the market as of 2003. The researchers focused mainly on small-molecule drugs, not biologics. That’s because of how the compounds are structured chemically. The complicated chemical makeup of...
View Details
- 31 Jan 2014
- News
Body, Heal Thyself
Chien and Derrick Rossi, published a paper in the journal Nature Biotechnology that showed mRNA Therapeutics was capable of stimulating blood vessel growth, repairing damaged heart tissue, and helping a mouse through myocardial...
View Details
- Web
Industry Information - Alumni
opportunities for professionals in the biotechnology and pharmaceutical industries. +–Hospitality Hospitality - General SmartBriefs – Travel Newsletter digest of hospitality industry headlines produced in partnership with several trade...
View Details
- January 2014 (Revised December 2014)
- Case
GenapSys: Business Models for the Genome
By: Richard G. Hamermesh, Joseph B. Fuller and Matthew Preble
GenapSys, a California-based startup, was soon to release a new DNA sequencer that the company's founder, Hesaam Esfandyarpour, believed was truly revolutionary. The sequencer would be substantially less expensive—potentially costing just a few thousand dollars—and... View Details
Keywords:
DNA Sequencing;
Life Sciences;
Business Model;
Innovation & Entrepreneurship;
Health Care and Treatment;
Genetics;
Business Strategy;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
United States
Hamermesh, Richard G., Joseph B. Fuller, and Matthew Preble. "GenapSys: Business Models for the Genome." Harvard Business School Case 814-050, January 2014. (Revised December 2014.)
- 20 Sep 2021
- Blog Post
Student Spotlight: Summer Internships in Business and Environment
fermentation in a carbon-negative biotechnology process. Solugen envisions a global-scale network of automated, carbon-sequestering mini-mills that are multi-product, drastically impacting the way chemicals are produced and transported...
View Details